A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®
Phase 4
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Anemia
Both
Anemia
Trial Information
A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®
Inclusion Criteria:
- Subjects with nonmyeloid malignancy(ies)
- Anemia (hgb less than or equal to 11.0 g/dL) due to cancer and chemotherapy
Exclusion Criteria:
- Subjects with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML),
myelodysplastic syndromes (MDS)
- Unstable cardiac disease or anemia due to other causes
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Patient reported outcomes
Principal Investigator
MD
Investigator Role:
Study Director
Investigator Affiliation:
Amgen
Authority:
United States: Institutional Review Board
Study ID:
20020132
NCT ID:
NCT00117117
Start Date:
September 2002
Completion Date:
December 2003
Related Keywords:
- Anemia
- Chemotherapy induced anemia
- Amgen
- Aranesp®
- darbepoetin alfa
- Anemia
Name | Location |
|---|
